Supervised clustering of peripheral immune cells associated with clinical response to checkpoint inhibitor therapy in patients with advanced melanoma

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Supervised clustering of peripheral immune cells associated with clinical response to checkpoint inhibitor therapy in patients with advanced melanoma. / Kverneland, A. H.; Thorsen, S. U.; Granhøj, J. S.; Hansen, F. S.; Konge, M.; Ellebæk, E.; Donia, M.; Svane, I. M.

In: Immuno-Oncology and Technology, Vol. 20, 100396, 2023.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Kverneland, AH, Thorsen, SU, Granhøj, JS, Hansen, FS, Konge, M, Ellebæk, E, Donia, M & Svane, IM 2023, 'Supervised clustering of peripheral immune cells associated with clinical response to checkpoint inhibitor therapy in patients with advanced melanoma', Immuno-Oncology and Technology, vol. 20, 100396. https://doi.org/10.1016/j.iotech.2023.100396

APA

Kverneland, A. H., Thorsen, S. U., Granhøj, J. S., Hansen, F. S., Konge, M., Ellebæk, E., Donia, M., & Svane, I. M. (2023). Supervised clustering of peripheral immune cells associated with clinical response to checkpoint inhibitor therapy in patients with advanced melanoma. Immuno-Oncology and Technology, 20, [100396]. https://doi.org/10.1016/j.iotech.2023.100396

Vancouver

Kverneland AH, Thorsen SU, Granhøj JS, Hansen FS, Konge M, Ellebæk E et al. Supervised clustering of peripheral immune cells associated with clinical response to checkpoint inhibitor therapy in patients with advanced melanoma. Immuno-Oncology and Technology. 2023;20. 100396. https://doi.org/10.1016/j.iotech.2023.100396

Author

Kverneland, A. H. ; Thorsen, S. U. ; Granhøj, J. S. ; Hansen, F. S. ; Konge, M. ; Ellebæk, E. ; Donia, M. ; Svane, I. M. / Supervised clustering of peripheral immune cells associated with clinical response to checkpoint inhibitor therapy in patients with advanced melanoma. In: Immuno-Oncology and Technology. 2023 ; Vol. 20.

Bibtex

@article{8c528cbfb1dd4254a2108c8ffe321a10,
title = "Supervised clustering of peripheral immune cells associated with clinical response to checkpoint inhibitor therapy in patients with advanced melanoma",
abstract = "Background and purpose: Immune therapy with checkpoint inhibitors (CPIs) is a highly successful therapy in many cancers including metastatic melanoma. Still, many patients do not respond well to therapy and there are no blood-borne biomarkers available to assess the clinical outcome. Materials and methods: To investigate cellular changes after CPI therapy, we carried out flow cytometry-based immune monitoring in a cohort of 90 metastatic melanoma patients before and after CPI therapy using the FlowSOM algorithm. To evaluate associations to the clinical outcome with therapy, we divided the patients based on progression-free survival. Results: We found significant associations with CPI therapy in both peripheral blood mononuclear cell and T-cell subsets, but with the most pronounced effects in the latter. Particularly CD4+ effector memory T-cell subsets were associated with response with a positive correlation between CD27+HLA-DR+CD4+ effector memory T cells in a univariate (odds ratio: 1.07 [95% confidence interval 1.02-1.12]) and multivariate regression model (odds ratio: 1.08 [95% confidence interval 1.03-1.14]). We also found a trend towards stronger accumulation of CD57+CD8+ T cells in non-responding patients. Conclusion: Our results show significant associations between immune monitoring and clinical outcome of therapy that could be evaluated as biomarkers in a clinical setting.",
keywords = "biomarkers, checkpoint inhibitors, immune monitoring, immune therapy, metastatic melanoma, supervised clustering",
author = "Kverneland, {A. H.} and Thorsen, {S. U.} and Granh{\o}j, {J. S.} and Hansen, {F. S.} and M. Konge and E. Elleb{\ae}k and M. Donia and Svane, {I. M.}",
note = "Publisher Copyright: {\textcopyright} 2023 The Author(s)",
year = "2023",
doi = "10.1016/j.iotech.2023.100396",
language = "English",
volume = "20",
journal = "Immuno-Oncology and Technology",
issn = "2590-0188",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Supervised clustering of peripheral immune cells associated with clinical response to checkpoint inhibitor therapy in patients with advanced melanoma

AU - Kverneland, A. H.

AU - Thorsen, S. U.

AU - Granhøj, J. S.

AU - Hansen, F. S.

AU - Konge, M.

AU - Ellebæk, E.

AU - Donia, M.

AU - Svane, I. M.

N1 - Publisher Copyright: © 2023 The Author(s)

PY - 2023

Y1 - 2023

N2 - Background and purpose: Immune therapy with checkpoint inhibitors (CPIs) is a highly successful therapy in many cancers including metastatic melanoma. Still, many patients do not respond well to therapy and there are no blood-borne biomarkers available to assess the clinical outcome. Materials and methods: To investigate cellular changes after CPI therapy, we carried out flow cytometry-based immune monitoring in a cohort of 90 metastatic melanoma patients before and after CPI therapy using the FlowSOM algorithm. To evaluate associations to the clinical outcome with therapy, we divided the patients based on progression-free survival. Results: We found significant associations with CPI therapy in both peripheral blood mononuclear cell and T-cell subsets, but with the most pronounced effects in the latter. Particularly CD4+ effector memory T-cell subsets were associated with response with a positive correlation between CD27+HLA-DR+CD4+ effector memory T cells in a univariate (odds ratio: 1.07 [95% confidence interval 1.02-1.12]) and multivariate regression model (odds ratio: 1.08 [95% confidence interval 1.03-1.14]). We also found a trend towards stronger accumulation of CD57+CD8+ T cells in non-responding patients. Conclusion: Our results show significant associations between immune monitoring and clinical outcome of therapy that could be evaluated as biomarkers in a clinical setting.

AB - Background and purpose: Immune therapy with checkpoint inhibitors (CPIs) is a highly successful therapy in many cancers including metastatic melanoma. Still, many patients do not respond well to therapy and there are no blood-borne biomarkers available to assess the clinical outcome. Materials and methods: To investigate cellular changes after CPI therapy, we carried out flow cytometry-based immune monitoring in a cohort of 90 metastatic melanoma patients before and after CPI therapy using the FlowSOM algorithm. To evaluate associations to the clinical outcome with therapy, we divided the patients based on progression-free survival. Results: We found significant associations with CPI therapy in both peripheral blood mononuclear cell and T-cell subsets, but with the most pronounced effects in the latter. Particularly CD4+ effector memory T-cell subsets were associated with response with a positive correlation between CD27+HLA-DR+CD4+ effector memory T cells in a univariate (odds ratio: 1.07 [95% confidence interval 1.02-1.12]) and multivariate regression model (odds ratio: 1.08 [95% confidence interval 1.03-1.14]). We also found a trend towards stronger accumulation of CD57+CD8+ T cells in non-responding patients. Conclusion: Our results show significant associations between immune monitoring and clinical outcome of therapy that could be evaluated as biomarkers in a clinical setting.

KW - biomarkers

KW - checkpoint inhibitors

KW - immune monitoring

KW - immune therapy

KW - metastatic melanoma

KW - supervised clustering

U2 - 10.1016/j.iotech.2023.100396

DO - 10.1016/j.iotech.2023.100396

M3 - Journal article

C2 - 37810199

AN - SCOPUS:85172692618

VL - 20

JO - Immuno-Oncology and Technology

JF - Immuno-Oncology and Technology

SN - 2590-0188

M1 - 100396

ER -

ID: 369925904